688265.SHG Shanghai Model Organisms Center Inc
- Market cap
- CNY 3.69B
- P/E
- 262.9x
- P/B
- 2.07x
- ROE
- 1.1%
- Dividend yield
- 0.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688265.SHG undervalued?
Graham numberThe Graham number of Shanghai Model Organisms Center Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Model Organisms Center Inc fundamental analysis
No fundamental analysis for Shanghai Model Organisms Center Inc yet.
Shanghai Model Organisms Center Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Model Organisms Center Inc
Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models. It uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene editing technology to introduce or delete target DNA fragments. The company offers toolbox of mice; disease mice, such as rare, infectious, and nervous system diseases, cardio-metabolic, autoimmune, and spontaneous tumor;…
Full company profileShanghai Model Organisms Center Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Model Organisms Center Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 60.5M | 76.3M | 121M | 155M | 196M | 275M | 303M | 367M | 381M | 421M | 465M |
| Gross Profit | 39.3M | 34.5M | 52.2M | 77.1M | 113M | 166M | 124M | 153M | 173M | 421M | 253M |
| Operating Income | 14.7M | -15.7M | 16.0M | 22.8M | 48.9M | 67.9M | -16.4M | -29.8M | 2.79M | 30.7M | 22.0M |
| EBITDA | 18.2M | -13.1M | 22.8M | 31.2M | 55.6M | 82.9M | 8.98M | -1.30M | 42.3M | 65.5M | 17.9M |
| Net Income | 14.6M | -16.1M | 15.1M | 23.2M | 44.6M | 60.9M | -5.40M | -20.6M | 6.50M | 32.4M | 18.2M |
| EPS | 1.50 | -0.31 | 0.29 | 0.44 | 0.78 | 1.04 | -0.07 | -0.26 | 0.08 | 0.43 | 0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 151M | 179M | 192M | 219M | 357M | 1.96B | 2.05B | 2.00B | 1.93B | 1.98B | 2.00B |
| Total Liabilities | 52.4M | 81.6M | 79.6M | 83.3M | 102M | 180M | 288M | 261M | 246M | 274M | 278M |
| Shareholders' Equity | 75.3M | 97.0M | 112M | 135M | 255M | 1.78B | 1.77B | 1.74B | 1.68B | 1.71B | 1.72B |
| Cash & Short-term Investments | 71.6M | 28.1M | 52.1M | 108M | 142M | 1.68B | 1.13B | 1.02B | 1.01B | 150M | 185M |
| Total Debt | - | - | - | - | 29.1M | 26.0M | 121M | 94.8M | 52.7M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 25.8M | 8.23M | 11.7M | 34.8M | 59.1M | 111M | 18.9M | 20.1M | 71.6M | 96.9M | - |
| Capital Expenditure | 27.1M | 44.8M | 2.49M | 2.16M | 103M | 52.4M | 270M | 124M | 25.2M | 45.6M | 81.6M |
| Free Cash Flow | -1.24M | -36.6M | 9.25M | 32.6M | -43.9M | 59.1M | -251M | -104M | 46.3M | 51.3M | -163M |
| Ratios | |||||||||||
| ROE | 19.4% | -16.5% | 13.5% | 17.2% | 17.5% | 3.4% | -0.3% | -1.2% | 0.4% | 1.9% | 1.1% |
| ROA | 9.7% | -9.0% | 7.9% | 10.6% | 12.5% | 3.1% | -0.3% | -1.0% | 0.3% | 1.6% | 0.9% |
| Net Profit Margin | 24.2% | -21.0% | 12.4% | 15.0% | 22.7% | 22.1% | -1.8% | -5.6% | 1.7% | 7.7% | 3.9% |
| Debt to Equity | - | - | - | - | 0.11x | 0.01x | 0.07x | 0.05x | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Model Organisms Center Inc dividends
- Dividend yield
- 0.27%
- Forward dividend
- 0.13 CNY
- Payout ratio
- -
- Ex-dividend date
- Jul 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 10.0M | 0.12 | 154.0% |
| 2023 | CNY 405K | 0.01 | - |
| 2022 | CNY 20.0M | 0.26 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Model Organisms Center Inc
- Insiders 73.66%
- Institutions 2.46%
- Public & others 23.88%
- Shares outstanding 78.0M
- Free float 31.7M
Shanghai Model Organisms Center Inc company profile
- Company name
- Shanghai Model Organisms Center Inc
- Ticker
- 688265.SHG
- ISIN
- CNE1000055L1
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 848
- Fiscal year end
- December
- Address
- No. 1, Lane 63, Shanghai, China, 201318
- Phone
- 86 21 2079 1155
- Website
- modelorg.com
About Shanghai Model Organisms Center Inc
Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models. It uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene editing technology to introduce or delete target DNA fragments. The company offers toolbox of mice; disease mice, such as rare, infectious, and nervous system diseases, cardio-metabolic, autoimmune, and spontaneous tumor; and target humanized knockins, which includes tumor targets, immune checkpoint, complements, cytokines, and metabolic and other targets, as well as cytokine reporters, inducible cell ablation, and cell-specific reporters. It also provides other models comprising rats, such as humanized drug target, immunodeficient, diseases, reporters, and cre-drivers; standard strains including inbred and outbred; cells model, which includes reporter labeled, primary, wild-type, and other; and supporting solutions including colony management, such as cryopreservation and cryorecovery, housing and management, genotyping analysis, and breeding services, as well as auxiliary apparatuses, such as e-BLOT WB imaging system. Further, the company provides preclinical services, which includes non-GLP toxicology, pharmacokinetics, phenotype analysis, and pharmacology and pharmacodynamics. It offers treatment for various therapeutic areas, such as oncology; nervous system, autoimmune, and digestive system diseases. The company was founded in 2000 and is headquartered in Shanghai, China.
Shanghai Model Organisms Center Inc management
4- Mr. Chunming ZhangGM and Chief Financial Officer · born 1969
- Mr. Xue YangBoard Secretary · born 1989
- Mr. Ruilin SunDeputy GM & Director · born 1980
- Mr. Dongxiao FengDeputy General Manager · born 1970